复发难治性鼻型结外NK/T细胞淋巴瘤的治疗研究进展  

Advances on the treatment of relapsed or refractory extranodal NK/T-cell lymphoma,nasal type

作　　者：张民安 王瑶 施文瑜[3] 张亚平[1] ZHANG Min'an;WANG Yao;SHI Wenyu;ZHANG Yaping(Department of Hematology,Affiliated Hospital of Nantong University,Nantong,226001,China;Hematology and Oncology Center,Hefei Cancer Hospital,Chinese Academy of Sciences;Department of Oncology,Affiliated Hospital of Nantong University)

机构地区：[1]南通大学附属医院血液科,江苏南通226001 [2]中国科学院合肥肿瘤医院血液肿瘤中心 [3]南通大学附属医院肿瘤科

出　　处：《临床血液学杂志》2023年第11期840-844,共5页Journal of Clinical Hematology

基　　金：中国博士后科学基金(No:2019M660127);江苏省博士后科研资助计划(No:2019Z146);南通市科技项目(No:JC2020049)。

摘　　要：鼻型结外NK/T细胞淋巴瘤(ENKTL)是侵袭性非霍奇金淋巴瘤的一种,临床预后较差。尽管目前临床上以左旋门冬酰胺酶为核心的多种化疗方案的应用使患者预后得到明显改善,但仍有部分患者治疗后出现复发或进展为难治性疾病。近年来,免疫调节治疗、单克隆抗体、信号通路靶向治疗、基因表达及表观调控等一系列治疗措施的应用为复发难治性ENKTL提供了新的方向。同时,相关药物的联合使用也取得了一定的成果,其在复发难治性ENKTL中得到应用并提高了患者的生存率和生活质量。Extranodal NK;T-cell lymphoma(ENKTL),nasal type is an aggressive form of non-Hodgkin lymphoma with a poor prognosis.Although the current multiple L-asparaginase-based therapy options have clearly improved outcomes in patients,a significant proportion of patients would relapse or progress with treatment-refractory disease after initial therapy.In recent years,application of multiple therapeutic measures,such as immunomodulatory treatments,monoclonal antibodies,targeting signaling pathways and epigenetic modifications,provides novel directions for the treatment of these relapsed or refractory patients.Concurrently,combination therapies of related drugs have also acquired some achievements,which have been applied in relapsed or refractory ENKTL and improve the survival and quality of life.

关 键 词：鼻型结外NK/T细胞淋巴瘤 复发难治性 靶向治疗 免疫治疗 联合治疗 

分 类 号：R733.4[医药卫生—肿瘤]